Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 4/28/24 → 4/28/26 |
Funding
- Merck Sharp & Dohme Corporation: $41,953.00
24-GU-85-MSD (004-00): A Phase 3, Randomized, Open-Label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with
- Myint, Zin (PI)